ReviewILAR journal2012
Cancer epigenetics: a brief review.
Review in ILAR journal, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of childhood and adolescence obesity with incidence and mortality of adulthood cancers. A systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- The Janus Face of SPAG6: Inducing EMT in Luminal Breast Cancer Cells Amidst Widespread Expression Loss in Breast Tumours.Journal of cellular and molecular medicine · 2025Article
- Placental and immune cell DNA methylation reference panel for bulk tissue cell composition estimation in epidemiological studies.Epigenetics · 2024Article
- CBX4 plays a bidirectional role in transcriptional regulation and lung adenocarcinoma progression.Cell death & disease · 2024Article
- Rational Computational Approaches in Drug Discovery: Potential Inhibitors for Allosteric Regulation of Mutant Isocitrate Dehydrogenase-1 Enzyme in Cancers.Molecules (Basel, Switzerland) · 2023Article
- KISS-1, Mediated by Promoter Methylation, Suppresses Esophageal Squamous Cell Carcinoma Metastasis via MMP2/9/MAPK Axis.Digestive diseases and sciences · 2022Article
- Article
- Bringing precision oncology to cellular resolution with single-cell genomics.Clinical & experimental metastasis · 2022Review
- Modulation of DNA/RNA Methylation by Small-Molecule Modulators and Their Implications in Cancer.Sub-cellular biochemistry · 2022Article
- Aberrant super-enhancer-driven oncogene ENC1 promotes the radio-resistance of breast carcinoma.Cell death & disease · 2021Article
- Epigenetics of aging and disease: a brief overview.Aging clinical and experimental research · 2021Review
- Epstein-Barr Virus Promotes B Cell Lymphomas by Manipulating the Host Epigenetic Machinery.Cancers · 2020Review
- Chiral discrimination in a mutated IDH enzymatic reaction in cancer: a computational perspective.European biophysics journal : EBJ · 2020Article
- Cell Types in Environmental Epigenetic Studies: Biological and Epidemiological Frameworks.Current environmental health reports · 2020Review
- Development and evaluation of a pH-responsive and water-soluble drug delivery system based on smart polymer coating of graphene nanosheets: anRSC advances · 2020Article
- Epigenetics and epilepsy prevention: The therapeutic potential of adenosine and metabolic therapies.Neuropharmacology · 2020Review
- Host proteome linked to HPV E7-mediated specific gene hypermethylation in cancer pathways.Infectious agents and cancer · 2020Article
- Roles of E-cadherin and Noncoding RNAs in the Epithelial-mesenchymal Transition and Progression in Gastric Cancer.International journal of molecular sciences · 2019Review
- DNA methylation from a Type I restriction modification system influences gene expression and virulence in Streptococcus pyogenes.PLoS pathogens · 2019Article
- Markers as mediators: A review and synthesis of epigenetics literature.BioSocieties · 2019Article
Corrections and comments
- Erratum issuedVirani, Shami [corrected to Virani, Shama]
Authors and funding
5 authors.
Funding
Abstract
Cancer is a disease that results from the successive accumulation of genetic and epigenetic alterations. Despite intense study, many unanswered questions about the nature of the contribution of epigenetic changes to carcinogenesis remain. In this review, we describe principles of epigenetics as they relate to our current understanding of carcinogenesis. There are a number of in vivo models of specific pathways of carcinogenesis that are very useful for the characterization of epigenetic mechanisms that link environmental exposures or genetic susceptibility and cancer progression. Because epigenetic alterations are thought to be reversible, they offer great promise for treatment of cancer. The use of animal models to evaluate the effects of decitabine and zebularine has elucidated the mechanisms of action and indicated the potential for these types of treatment. Ultimately, the greatest challenge lies in the integration of laboratory and epidemiologic data to best prevent and treat this deadly disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.